| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonçales Jr, ... New England journal of medicine 347 (13), 975-982, 2002 | 8634 | 2002 |
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B GKK Lau, T Piratvisuth, KX Luo, P Marcellin, S Thongsawat, G Cooksley, ... New England Journal of Medicine 352 (26), 2682-2695, 2005 | 1984 | 2005 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1495 | 2014 |
| A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness L Stuyver, S De Gendt, C Van Geyt, F Zoulim, M Fried, RF Schinazi, ... Journal of general virology 81 (1), 67-74, 2000 | 1489 | 2000 |
| Side effects of therapy of hepatitis C and their management MW Fried Hepatology 36 (S1), S237-S244, 2002 | 1266 | 2002 |
| Response-guided telaprevir combination treatment for hepatitis C virus infection KE Sherman, SL Flamm, NH Afdhal, DR Nelson, MS Sulkowski, ... New England Journal of Medicine 365 (11), 1014-1024, 2011 | 1043 | 2011 |
| Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis MP Curry, JG O’Leary, N Bzowej, AJ Muir, KM Korenblat, JM Fenkel, ... New England Journal of Medicine 373 (27), 2618-2628, 2015 | 954 | 2015 |
| Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ... Gastroenterology 149 (3), 649-659, 2015 | 949 | 2015 |
| Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B R McKenzie, MW Fried, R Sallie, H Conjeevaram, AM Di Bisceglie, Y Park, ... New England Journal of Medicine 333 (17), 1099-1105, 1995 | 719 | 1995 |
| Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review O Falade-Nwulia, C Suarez-Cuervo, DR Nelson, MW Fried, JB Segal, ... Annals of internal medicine 166 (9), 637-648, 2017 | 711 | 2017 |
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonçales Jr, ... Journal of hepatology 43 (3), 425-433, 2005 | 673 | 2005 |
| Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised … IM Jacobson, GJ Dore, GR Foster, MW Fried, M Radu, VV Rafalsky, ... The Lancet 384 (9941), 403-413, 2014 | 634 | 2014 |
| Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 HS Conjeevaram, MW Fried, LJ Jeffers, NA Terrault, TE Wiley–Lucas, ... Gastroenterology 131 (2), 470-477, 2006 | 594 | 2006 |
| Liver transplantation for acute liver failure from drug induced liver injury in the United States MW Russo, JA Galanko, R Shrestha, MW Fried, P Watkins Liver Transplantation 10 (8), 1018-1023, 2004 | 591 | 2004 |
| Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C KR Reddy, TL Wright, PJ Pockros, M Shiffman, G Everson, R Reindollar, ... Hepatology 33 (2), 433-438, 2001 | 533 | 2001 |
| Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study ME Eyster, MW Fried, AM Di Bisceglie, JJ Goedert | 491 | 1994 |
| Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial AM Di Bisceglie, HS Conjeevaram, MW Fried, R Sallie, Y Park, ... Annals of internal medicine 123 (12), 897-903, 1995 | 480 | 1995 |
| A pilot study of ribavirin therapy for chronic hepatitis C AM di Bisceglie, M Shindo, TL Fong, MW Fried, MG Swain, NV Bergasa, ... Hepatology 16 (3), 649-654, 1992 | 377 | 1992 |
| Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naive genotype 1 hepatitis C: the randomized PILLAR study MW Fried, M Buti, GJ Dore, R Flisiak, P Ferenci, I Jacobson, P Marcellin, ... Hepatology 58 (6), 1918-1929, 2013 | 373 | 2013 |
| Side effects of therapy for chronic hepatitis C MW Russo, MW Fried Gastroenterology 124 (6), 1711-1719, 2003 | 364 | 2003 |
